NCT02905864

Liraglutide 3 mg for Knee Osteoarthritis

Effect of Liraglutide on Body Weight and Pain in Overweight or Obese Patients With Knee Osteoarthritis: A Randomised, Double Blind, Placebo-controlled, Parallel Group, Single-centre Trial

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 150 (estimated)
• Sponsor: Henrik Gudbergsen · Academic / Other
• Sex: All
• Age: 18 Years – 74 Years
• Healthy volunteers: Not accepted

Summary

A randomised, double blind, placebo-controlled, parallel group, and single-centre trial investigating the effect of liraglutide on body weight and pain in overweight or obese patients with knee osteoarthritis. Patients will be subjected to a run-in diet intervention phase (week -8 to 0) including a low-calorie diet and dietetic counselling. At week 0 patients will be randomised to receive either liraglutide 3 mg or liraglutide 3 mg placebo as an add-on to dietetic guidance on re-introducing regular foods and a focus on continued motivation to engage in a healthy lifestyle.

Conditions

• Osteoarthritis
• Obesity

Interventions

Type	Name	Description
DRUG	Liraglutide 3 mg (Saxenda)
DRUG	Liraglutide 3 mg placebo

Timeline

• Start date: 2016-11-01
• Primary completion: 2019-02-01
• Completion: 2019-03-01
• First posted: 2016-09-19
• Last updated: 2019-03-25

Locations

1 site across 1 country: Denmark